

ASX Listing Rule 4.10.19

MELBOURNE, AUSTRALIA, 28 August 2024: Cleo Diagnostics Limited (ASX: COV or the Company) released its Annual Report for the period ended 30 June 2024 on the 27 August 2024. The following statement is provided, as it was inadvertently omitted from the Annual Report.

In accordance with Listing Rule 4.10.19, the Company states that it has used the cash and assets in a form readily convertible to cash that it had at the time of admission in a way consistent with its business objectives.

For and on behalf of the Board.



Ms Pauline Moffatt
Company Secretary

Cleo Diagnostics Ltd ASX:COV

Level 2, 480 Collins Street, Melbourne, VIC, 3000
ACN 655 717 169 T +61 3 9614 0600 E office@cleodx.com

Directors
Chair and Non-Executive Director **Adrien Wing**
Chief Executive Officer and Executive Director **Dr Richard Allman**
Chief Scientific Officer and Executive Director **Dr Andrew Stephens**
Non-Executive Director and Lead Medical Advisor **Professor Tom Jobling**
Non-Executive Director **Lucinda Nolan**

cleodx.com